Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Alan Gamis"'
Autor:
Abdelrahman H. Elsayed, Xueyuan Cao, Richard J. Marrero, Nam H. K. Nguyen, Huiyun Wu, Yonhui Ni, Raul C. Ribeiro, Herold Tobias, Peter J. Valk, François Béliveau, Guillaume Richard-Carpentier, Josée Hébert, C. Michel Zwaan, Alan Gamis, Edward Anders Kolb, Richard Aplenc, Todd A. Alonzo, Soheil Meshinchi, Jeffrey Rubnitz, Stanley Pounds, Jatinder K. Lamba
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract In this study, we leveraged machine-learning tools by evaluating expression of genes of pharmacological relevance to standard-AML chemotherapy (ara-C/daunorubicin/etoposide) in a discovery-cohort of pediatric AML patients (N = 163; NCT001360
Externí odkaz:
https://doaj.org/article/8d2e5546c18f4cf3998b81a1211405a0
Autor:
Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd Alonzo, John Choi, Brian Fisher, Robert Gerbing, Betsy Hirsch, Terzah Horton, Samir Kahwash, John Levine, Michael Loken, Lisa Brodersen, Jessica Pollard, Susana Raimondi, Edward Anders Kolb, Alan Gamis
Publikováno v:
Haematologica, Vol 105, Iss 7 (2020)
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to stand
Externí odkaz:
https://doaj.org/article/1923b3bd287f4e0aa61b66541e8b65bc
Autor:
Katherine Tarlock, Maria Luisa Sulis, Joseph H. Chewning, Jessica A. Pollard, Todd Cooper, Alan Gamis, Shalini Shenoy, Matthew Kutny, John Horan, Soheil Meshinchi, Jaap-Jan Boelens, Marie Bleakley, Paul A. Carpenter, E. Anders Kolb
Publikováno v:
Transplantation and Cellular Therapy. 28:530-545
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::669c4b29595b4da1752260eed4ee08ca
https://doi.org/10.1016/j.jtct.2022.06.005
https://doi.org/10.1016/j.jtct.2022.06.005
Autor:
Jatinder K. Lamba, Soheil Meshinchi, Alan Gamis, Raul C. Ribeiro, Jeffrey E. Rubnitz, Xueyuan Cao, Stanley Pounds, Janet Franklin, Susana Raimondi, Betsy Hirsch, Michael R. Loken, Jessica A. Pollard, Amit K. Mitra, Robert B. Gerbing, Roland B. Walter, Todd A. Alonzo, Leslie Mortland
Supplementary Table 2. Characteristics of pediatric AML patients treated on St. Jude AML02 trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eb316bad638afbd2f6678728480de35
https://doi.org/10.1158/1078-0432.22452522.v1
https://doi.org/10.1158/1078-0432.22452522.v1
Autor:
Jatinder K. Lamba, Soheil Meshinchi, Alan Gamis, Raul C. Ribeiro, Jeffrey E. Rubnitz, Xueyuan Cao, Stanley Pounds, Janet Franklin, Susana Raimondi, Betsy Hirsch, Michael R. Loken, Jessica A. Pollard, Amit K. Mitra, Robert B. Gerbing, Roland B. Walter, Todd A. Alonzo, Leslie Mortland
Supplementary Table 1. Characteristics of pediatric AML patients treated on AAML03P1 trial by four CD33 SNPs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4b90ee960f223e00969281f6eca97a
https://doi.org/10.1158/1078-0432.22452525
https://doi.org/10.1158/1078-0432.22452525
Autor:
Jatinder K. Lamba, Soheil Meshinchi, Alan Gamis, Raul C. Ribeiro, Jeffrey E. Rubnitz, Xueyuan Cao, Stanley Pounds, Janet Franklin, Susana Raimondi, Betsy Hirsch, Michael R. Loken, Jessica A. Pollard, Amit K. Mitra, Robert B. Gerbing, Roland B. Walter, Todd A. Alonzo, Leslie Mortland
Purpose: The purpose of this study was to evaluate clinical implications of CD33 single-nucleotide polymorphisms (SNP) in pediatric patients with acute myeloid leukemia (AML) treated with gemtuzumab-ozogamicin (GO)–based therapy.Experimental Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3acb29442155e1f2616f7003b8126451
https://doi.org/10.1158/1078-0432.c.6522501.v1
https://doi.org/10.1158/1078-0432.c.6522501.v1
Autor:
Abdelrahman H. Elsayed, Xueyuan Cao, Amit K. Mitra, Huiyun Wu, Susana Raimondi, Christopher Cogle, Zeina Al-Mansour, Raul C. Ribeiro, Alan Gamis, Edward Anders Kolb, Richard Aplenc, Todd A. Alonzo, Soheil Meshinchi, Jeffrey Rubnitz, Stanley Pounds, Jatinder K. Lamba
Publikováno v:
J Clin Oncol
PURPOSE To establish a patient-specific polygenic score derived from cytarabine (ara-C) pathway pharmacogenomic evaluation to personalize acute myeloid leukemia (AML) treatment. MATERIALS AND METHODS Single nucleotide polymorphisms (SNPs) in the ara-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cd11c2f0d1bfa183c487fd42f87915c
https://doi.org/10.1200/jco.21.01422
https://doi.org/10.1200/jco.21.01422
Autor:
Mohammed O. Gbadamosi, Vivek M. Shastri, Abdelrahman H. Elsayed, Rhonda Ries, Oluwaseyi Olabige, Nam H. K. Nguyen, Angelica De Jesus, Yi-Cheng Wang, Alice Dang, Betsy A. Hirsch, Todd A. Alonzo, Alan Gamis, Soheil Meshinchi, Jatinder K. Lamba
Publikováno v:
Leukemia
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody linked to calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating acute myeloid leukemia (AML). In this study, we used LASSO regression modeling to develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::291cbb6a7f2574af2ab5aaadaa2c91ab
https://europepmc.org/articles/PMC9357169/
https://europepmc.org/articles/PMC9357169/
Publikováno v:
Frontiers in Genetics, Vol 7 (2016)
Regression analysis is commonly used in genome-wide association studies (GWAS) to test genotype-phenotype associations but restricts the phenotype to a single observation for each individual. There is an increasing need for analytic methods for longi
Externí odkaz:
https://doaj.org/article/0c8d71514a144af481162d1e6b373d35
Autor:
Lauren Pommert, Todd M. Cooper, Robert B. Gerbing, Lisa Brodersen, Michael Loken, Alan Gamis, Richard Aplenc, Todd A. Alonzo, Edward Anders Kolb
Publikováno v:
Cancers, Vol 14, Iss 616, p 616 (2022)
Cancers; Volume 14; Issue 3; Pages: 616
Cancers; Volume 14; Issue 3; Pages: 616
International Working Group (IWG) and European LeukemiaNet (ELN) response definitions are utilized to evaluate the efficacy of new agents for childhood acute myeloid leukemia (AML) for regulatory purposes. However, these criteria are not consistent w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4757f8735a59a4c881c77258c2c605
https://www.mdpi.com/2072-6694/14/3/616
https://www.mdpi.com/2072-6694/14/3/616